Investigator-Initiated Research on Genetic Counseling Processes and Practices (R01, Clinical Trial Optional)
Funding Opportunity RFA-HG-20-048 from the NIH Guide for Grants and Contracts. The purpose of this initiative is to support investigator-initiated research on genetic counseling processes and practices in genomic medicine. Research is needed to optimize the genetic counseling process in the context of limited resources. Grants will assess, innovate, scale, and/or research the implementation of novel genetic counseling practices to address the need for more healthcare professionals trained in genetic counseling; the uneven access to in-person genetic counseling across U.S. health care systems, and the challenges of effec...
Source: NIH Funding Opportunities (Notices, PA, RFA) - July 30, 2020 Category: Research Source Type: funding
Investigator-Initiated Research on Genetic Counseling Processes and Practices (R21, Clinical Trial Optional)
Funding Opportunity RFA-HG-20-049 from the NIH Guide for Grants and Contracts. The purpose of this initiative is to support targeted studies on genetic counseling processes and practices in genomic medicine. Research is needed to optimize the genetic counseling process in the context of limited resources. Grants will assess, innovate, scale, and/or research the implementation of novel genetic counseling practices to address the need for more healthcare professionals trained in genetic counseling; the uneven access to in-person genetic counseling across U.S. health care systems, and the challenges of effective and effici...
Source: NIH Funding Opportunities (Notices, PA, RFA) - July 30, 2020 Category: Research Source Type: funding
Notice of Correction to PAR-19-223, "Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional)"
Notice NOT-DA-20-076 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - July 29, 2020 Category: Research Source Type: funding
Notice of Correction to PAR-20-225, "Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional)"
Notice NOT-DA-20-075 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - July 28, 2020 Category: Research Source Type: funding
Fertility Status as a Marker for Overall Health (R01 Clinical Trial Optional)
Funding Opportunity PAR-20-281 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity (FOA) is to support research that explores the premise that fertility status can be a marker for overall health. Chronic conditions such as concer, diabetes, and obesity can impair fertility, however, less is known about the extent to which fertility status can impact or acts as a marker for overall health. Data suggest that infertility is not necessarily a unique disease of the reproductive axis but is often physiologically or genetically linked with other diseases and conditions. Recent epidemiologic stu...
Source: NIH Funding Opportunities (Notices, PA, RFA) - July 23, 2020 Category: Research Source Type: funding
Fertility Status as a Marker for Overall Health (R21 Clinical Trial Not Allowed)
Funding Opportunity PAR-20-282 from the NIH Guide for Grants and Contracts. T?he purpose of this funding opportunity announcement (FOA) is to support exploratory/developmental research that explores the premise that fertility status can be a marker for overall health. Chronic conditions such as cancer, diabetes, and obesity can impair fertility, however, less is known about the extent to which fertility status can impact or act as a marker for overall health. Data suggest that infertility is not necessarily a unique disease of the reproductive axis but is often physiologically or genetically linked with other diseases a...
Source: NIH Funding Opportunities (Notices, PA, RFA) - July 23, 2020 Category: Research Source Type: funding
Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)
Funding Opportunity PAR-20-277 from the NIH Guide for Grants and Contracts. Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) along with the National Human Genome Research Institute (NHGRI) and National Institute of Dental and Craniofacial Research (NIDCR) encourages submission of applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate the genetic architecture of cancer risk and related outcomes (e.g., risk prediction or reduction, survival, or response to treatment, etc.). The goal of...
Source: NIH Funding Opportunities (Notices, PA, RFA) - July 22, 2020 Category: Research Source Type: funding
Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)
Funding Opportunity PAR-20-276 from the NIH Guide for Grants and Contracts. Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) along with the National Human Genome Research Institute (NHGRI) and National Institute of Dental and Craniofacial Research (NIDCR) encourages submission of applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate the genetic architecture of cancer risk and related outcomes (e.g., risk prediction or reduction, survival, or response to treatment, etc.). The goal of...
Source: NIH Funding Opportunities (Notices, PA, RFA) - July 22, 2020 Category: Research Source Type: funding
BRAIN Initiative: Tools for Germline Gene Editing in Marmosets (U01 - Clinical Trial Not Allowed)
Funding Opportunity RFA-DA-21-006 from the NIH Guide for Grants and Contracts. The purpose of this FOA isto develop tools and technologies to conduct cientifically rigorous, ethical, efficient, and cost-effective research infrastructure that supports germline and somatic transgenic and gene editing studies in the common marmoset (Callithrix jacchus). These studies should to answer crucial scientific questions that require genetic perturbation in a non-human primate model organism with the aim of supporting BRAIN goals of understanding the brain in health an disease. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - July 17, 2020 Category: Research Source Type: funding
Using Human Cell Animal Chimera Brains to Study HIV Latency and Pathology R01 - Clinical Trials Not Allowed
Funding Opportunity RFA-DA-21-026 from the NIH Guide for Grants and Contracts. Recent technical advancements have enabled generating human cell-mice chimeric brains by engrafting human iPSC-derived primitive neural progenitor cells and/or cord blood-derived microglial progenitor cells into neonatal mouse. In the chimeric brain, human neural progenitor cells or microglial cells differentiate, migrate, and distribute throughout the mouse brain. They are eventually functionally integrated into various brain regions. Such successes provide opportunities to define the structure, function, genetics and plasticity of functiona...
Source: NIH Funding Opportunities (Notices, PA, RFA) - July 13, 2020 Category: Research Source Type: funding
Center for Inherited Disease Research (CIDR) High Throughput Sequencing and Genotyping Resource Access (X01)
Funding Opportunity PAR-20-230 from the NIH Guide for Grants and Contracts. The Center for Inherited Disease Research (CIDR) high-throughput genotyping, sequencing and supporting statistical genetics services are designed to aid the identification of genes or genetic modifications that contribute to human health and disease or to enhance existing collections of well-phenotyped specimens by the addition of genotype or next-generation sequence data. The laboratory specializes in genomic services that cannot be efficiently carried out in individual investigator laboratories. CIDR provides the most up-to-date platforms, ser...
Source: NIH Funding Opportunities (Notices, PA, RFA) - June 11, 2020 Category: Research Source Type: funding
Emergency Awards: SARS-CoV-2 Serological Sciences Centers of Excellence (U54 Clinical Trial Optional)
Funding Opportunity RFA-CA-20-038 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is associated with the COVID-19 Supplement funded through the Paycheck Protection Program and Health Care Enhancement Act (P.L. 116-139) which directs the National Cancer Institute of the NIH to develop, validate, improve, and implement serological testing and associated technologies . The purpose of the FOA is to establish Serological Sciences Centers of Excellence with the goal of identifying and advancing research opportunities to characterize the immune responses elicited by SARS-CoV-2 viral inf...
Source: NIH Funding Opportunities (Notices, PA, RFA) - June 5, 2020 Category: Research Source Type: funding
Emergency Awards: Research Projects in SARS-CoV-2 Serological Sciences (U01 Clinical Trial Optional)
Funding Opportunity RFA-CA-20-039 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is associated with the COVID-19 Supplement funded through the Paycheck Protection Program and Health Care Enhancement Act (P.L. 116-139) which directs the National Cancer Institute of the NIH to develop, validate, improve, and implement serological testing and associated technologies. The purpose of the FOA is to establish Serological Sciences Research Projects with the goals of: identifying and advancing research opportunities to characterize the immune responses elicited by SARS-CoV-2 viral infect...
Source: NIH Funding Opportunities (Notices, PA, RFA) - June 5, 2020 Category: Research Source Type: funding
Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional)
Funding Opportunity PAR-20-225 from the NIH Guide for Grants and Contracts. Avenir means future in French, and this award looks toward the future by supporting early stage investigators proposing highly innovative studies. The award will support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow's leaders in the field. NIDA has developed two Avenir Award Programs, one for HIV/AIDS research and the other for genetics or epigenetics studies. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - June 1, 2020 Category: Research Source Type: funding
Limited Competition: National Primate Research Centers (P51) Program
Funding Opportunity PAR-20-181 from the NIH Guide for Grants and Contracts. This FOA encourages grant applications that support the activities of the National Primate Research Centers (NPRCs). Nonhuman primates (NHPs) are most closely related to humans, both physiologically and genetically. Therefore, NHPs are critical animal models for basic and translational research aimed at understanding human biology, both in normal and diseased states. Proper husbandry and management of NHPs require specialized physical and intellectual resources, which are most effectively and economically provided in centralized primate centers,...
Source: NIH Funding Opportunities (Notices, PA, RFA) - May 4, 2020 Category: Research Source Type: funding
